drugset
drugset / Trial / NCT06086522

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

NCT06086522 ↗

Phase 1 Recruiting 54 enrolled Qualigen Theraputics, Inc. Translational Drug Development · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.

Timeline

Start
2023-11-01
Primary completion
2025-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject QN-302 Small molecule — Intravenous

Indications

cancer